As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Aktis Oncology, Inc. The largest reported stake is Mpm Bioventures 2018, L.P.'s, at 19.3%. 5 filings are on record since January 14, 2026 (Schedule 13D, January 20, 2026).
Sell to companies like Aktis Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Blue Owl Capital Holdings LP · Percent: 5.92% · SCHEDULE 13G
- · Holder: EcoR1 Capital, LLC · Percent: 9.1% · SCHEDULE 13D
- · Holder: Mpm Bioventures 2018, L.P. · Percent: 19.3% · SCHEDULE 13D
- · Holder: Eli Lilly and Company · Percent: 11.9% · SCHEDULE 13D
- · Holder: VV Manager II LLC · Percent: 10.9% · SCHEDULE 13D
Aktis Oncology, Inc. has 5 Schedule 13D or 13G filings on record since 2026-01-14. 5 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Mpm Bioventures 2018, L.P. | 19.3% | 3,950,528 | SCHEDULE 13D, 2026-01-20 | 2026-01-12 |
| Eli Lilly and Company | 11.9% | 6,344,114 | SCHEDULE 13D, 2026-01-15 | 2026-01-12 |
| VV Manager II LLC | 10.9% | 5,829,212 | SCHEDULE 13D, 2026-01-14 | 2026-01-12 |
| EcoR1 Capital, LLC | 9.1% | 4,824,469 | SCHEDULE 13D, 2026-01-20 | 2026-01-12 |
| Blue Owl Capital Holdings LP | 5.92% | 3,161,348 | SCHEDULE 13G, 2026-05-14 | 2026-03-31 |
Holding shares or following this stake? See who's behind Aktis Oncology, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Aktis Oncology, Inc. and the records around it.
Aktis Oncology, Inc. elsewhere on the record
- Leadership changes Apr 2026
- Who owns it
Companies that share a holder
- Eli Lilly and Company also filed stake reports on 5 other companies: TRex Bio, Inc. (Oct 2026), Scribe Therapeutics, Inc. (Jul 2026), Ionetix Corp / DE / (Jul 2026)
- Blue Owl Capital Holdings LP also filed stake reports on 10 other companies: Context Therapeutics Inc. (Aug 2026), enGene Therapeutics Inc. (Aug 2026), ImageneBio, Inc. (May 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
Watch Aktis Oncology, Inc.
Get an email when Aktis Oncology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aktis Oncology, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aktis Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aktis Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
VV Manager II LLC
The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. The Reporting Individual is a member of the Issuer's board of directors. In addition, Ms. Kim, in her capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock options or other equity awards, pursuant to the Issuer's non-employee director compensation policy, …The first part of Item 4 of the SCHEDULE 13D filed 2026-01-14; the filing has the rest
Eli Lilly and Company
The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis. Except as set forth herein, the Reporting Person does not currently have any specific plan or proposal to acquire or dispose of Common Stock of the Issuer or any securities exercisable for or convertible into Common Stock of the Issuer, but the Reporting Person, consistent with its investment purpose, may at any time and from time to time directly or indirectly acquire additional or all shares of Common Stock, securities exercisable for or convertible into Common Stock of the Issuer, or other securities of the Issuer, or dispose of any or all of its shares of Common Stock, securities exercisable for or convertible into Common Stock of the Issuer, or other securities of the Issuer. The Reporting Person's determination to make any such acquisitions or dispositions, in each such case, will depend upon a variety of factors, including, but not limited to, an ongoing evaluation of its investment in such securities, applicable legal and/or contractual restrictions, prevailing market conditions, other investment opportunities, liquidity requirements of the Reporting Person and/or other investment considerations. In addition, in connection with the foregoing, the Reporting Person may engage in hedging or other transactions with respect to securities of the Issuer, including but not limited to, swaps and other …The first part of Item 4 of the SCHEDULE 13D filed 2026-01-15; the filing has the rest
EcoR1 Capital, LLC
Oleg Nodelman, the manager of EcoR1, is a member of the Issuer's board of directors. The reporting persons acquired securities of the Issuer for investment purposes based on their belief that the Issuer's securities represented an attractive investment opportunity. The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Common Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, and other investment considerations. Depending on their evaluation of various factors, the reporting persons may take such actions regarding their holdings of the Issuer's securities as they deem appropriate in light of circumstances existing from time to time. Such actions may include purchasing additional Common Stock in the open market, through privately negotiated transactions with third parties or otherwise, converting shares of Class A Common Stock into shares of Common Stock and selling at any time, in the open market, through privately negotiated transactions with third parties or otherwise, all or part of the Common Stock or other securities that they now own or hereafter acquire. The reporting persons also may from time to time enter into or unwind …The first part of Item 4 of the SCHEDULE 13D filed 2026-01-20; the filing has the rest
Mpm Bioventures 2018, L.P.
The MPM Entities acquired the securities reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer. Although the Reporting Persons currently have no plan or proposal to acquire any additional Issuer securities or to dispose of any of the Issuer securities reported herein, the Reporting Persons may, from time to time, acquire additional equity securities or debt securities of the Issuer, which debt securities may be convertible or non-convertible, secured or unsecured, or dispose of Issuer securities they beneficially own, on the open market or in private transactions or otherwise (including by means of 10b5-1 programs), consistent with their investment purposes and in amounts, on such terms and at such times as to be determined by the Reporting Persons based upon a number of factors, including, without limitation, their ongoing assessment of the Issuer's business prospects, the availability of Issuer securities at prices that would make the purchase or sale of such securities desirable, prevailing market conditions, the availability of other investment opportunities, and/or other considerations. In addition, consistent with their investment purpose, the Reporting Persons may engage in communications with persons associated with the Issuer, including stockholders of the Issuer, officers of the Issuer, members of the board of directors of the Issuer, and/or or other third parties, to discuss matters regarding the …The first part of Item 4 of the SCHEDULE 13D filed 2026-01-20; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-14 | VV Manager II LLC | 10.9% | SCHEDULE 13D |
| 2026-01-15 | Eli Lilly and Company | 11.9% | SCHEDULE 13D |
| 2026-01-20 | EcoR1 Capital, LLC | 9.1% | SCHEDULE 13D |
| 2026-01-20 | Mpm Bioventures 2018, L.P. | 19.3% | SCHEDULE 13D |
| 2026-05-14 | Blue Owl Capital Holdings LP | 5.92% | SCHEDULE 13G |
Questions about who owns Aktis Oncology, Inc.
Who owns Aktis Oncology, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Aktis Oncology, Inc.: Mpm Bioventures 2018, L.P. (19.3%, Schedule 13D, filed 2026-01-20), Eli Lilly and Company (11.9%, Schedule 13D, filed 2026-01-15), VV Manager II LLC (10.9%, Schedule 13D, filed 2026-01-14), EcoR1 Capital, LLC (9.1%, Schedule 13D, filed 2026-01-20) and Blue Owl Capital Holdings LP (5.92%, Schedule 13G, filed 2026-05-14).
Who are the largest shareholders of Aktis Oncology, Inc.?
By the share each holder's latest filing reports, the largest holders of Aktis Oncology, Inc. on this page are Mpm Bioventures 2018, L.P. (19.3%), Eli Lilly and Company (11.9%) and VV Manager II LLC (10.9%).
When did Mpm Bioventures 2018, L.P. buy into Aktis Oncology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Mpm Bioventures 2018, L.P. on this page is the Schedule 13D, filed 2026-01-20, reporting 19.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Aktis Oncology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 16, 2026 | Leadership change: Glenn Gormley appointed, Director | — | Leadership changes | Source |
| January 9, 2026 | IPO filing, Form 424B4 | $18 a share | IPO filings | Source |
| January 7, 2026 | IPO filing, Form S-1/A | $16 to $18 a share | IPO filings | Source |
| January 5, 2026 | IPO filing, Form S-1/A | $16 to $18 a share | IPO filings | Source |
| December 19, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Aktis Oncology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.